ClinicalTrials.gg
RecruitingNCT06632457Updated Nov 12, 2026

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

A Phase 3 interventional study of Survodutide and Placebo matching survodutide in Metabolic Dysfunction Associated Steatohepatitis, sponsored by Boehringer Ingelheim. Recruiting at 449 sites in 37 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Nov 12, 2026First site in Hong KongSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,590
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 211 studies in Fatty Liver with a site in United States — 41 open to participants now, 47 under way, 8 of them phase 3. Fatty Liver · United States.

Planned enrollment
6th of 162
1,590 · median 45
Started
2024
with 11 others
Phase 3
15 of 211
8 open now
Primary completion
2029-06
later than 39 of 46 live
Registered
183rd of 211
by date

Among the 211 studies in Fatty Liver with a site in United States, this one is the 6th largest by planned enrollment of the 162 interventional ones that give a count, is one of 12 that started in 2024, is one of 15 in phase 3, reaches primary completion later than 39 of the 46 other live ones, and was the 183rd registered.

Fatty Liver

663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

41 of the 211 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 211 studies in Fatty Liver with a site in United States, or all of them as a file.
02

Study summary

This study is open to adults who are at least 18 years old and have:

  • A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or
  • A confirmed liver disease called metabolic-associated steatohepatitis (MASH)
  • BMI of 27 kg/m2 or more or
  • 25 kg/m2 or more if the participant is Asian.

People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with NASH or MASH improve their liver function.

Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Each participant has twice the chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week. All participants regularly receive counselling to make changes to their diet and to exercise regularly.

Participants are in the study for up to 4 and a half years. During this time, they visit the study site or have a remote visit by video call every 2, 4 or 6 weeks for about a 1 year and 5 months. After this time participants visit the trial site or have a remote visit every 3 months until the end of the study.

The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. At some visits the liver parameters are measured using different imaging methods. The participants also fill in questionnaires about their symptoms. The results are compared between the groups to see whether the treatment works.

03

Conditions studied

  • Metabolic Dysfunction Associated Steatohepatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adults ≥18 years of age at the time of screening, and at least the legal age of consent in countries where it is >18 years
  2. (BMI) ≥27 kg/m2(≥25 kg/m2 for Asian trial participants)
  3. Compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.
  4. Magnetic resonance imaging proton density fat fraction (MRI-PDFF) fat fraction ≥5% or FibroScan® with controlled attenuation parameter (CAP) ≥288 dB/m, obtained during the screening period or a historic MRI-PDFF ≤12 weeks prior to randomisation (except for patients with 'cryptogenic cirrhosis' where MRI-PDFF \<5% or FibroScan® with CAP \<288 dB/m is allowed). This inclusion criterion does not apply for participants with a recent (≤12 months prior to randomisation) liver showing steatosis/steatohepatitis.
  5. Further inclusion criteria apply.

Exclusion criteria

Exclusion criteria:

  1. Current or history (\<5 years) of significant alcohol consumption, defined as an average of >140 g/week in female patients and >210 g/week in male patients, for a period of >3 consecutive months, or an inability to reliably quantify alcohol consumption based upon judgment of the investigator.
  2. Model of end-stage liver Disease (MELD) score >12 due to liver disease
  3. History or current (i.e. at screening) hepatic decompensation event of any of the following but not limited to:

    • Portal hypertension-related upper gastrointestinal (GI) bleeding
    • Ascites
    • Hepatic encephalopathy (HE) ≥Grade 1 according to the West Haven criteria
  4. Any of the following lab test result at screening

    • Albumin below \<3.5 g/dL (\<35.0 g/L)
    • (INR) >1.3 unless due to therapeutic anticoagulants
    • Total (TBL) >1.2x (ULN) NOTE: Trial participants with Gilbert Syndrome are eligible with a TBL >1.2x ULN if reticulocyte count is within normal limits, is within normal limits unless due to chronic anaemia and unrelated to haemolysis, and direct bilirubin is \<20% of TBL.
    • Alkaline phosphatase >1.5x ULN
    • \<100,000/µL (\<100 GI/L)
  5. History or evidence of other chronic liver diseases, such as primary biliary cholangitis, primary sclerosing cholangitis, hepatitis or overlap syndrome, Wilson's disease, alpha-1-antitrypsin deficiency, or genetic haemochromatosis
  6. positive (defined as positive hepatitis B surface antigen (HBsAg)) or history of chronic HBV infection
  7. positive (defined as positive hepatitis C virus (HCV) antibody and a positive HCV ribonucleic acid (RNA))
  8. Serum (AST) and/or alanine aminotransferase (ALT) >5x ULN
  9. Evidence of alcoholic liver disease, or drug-induced liver disease, as defined on the basis of typical exposure and history
  10. History of liver transplantation or listed for liver transplantation
  11. History of transjugular intrahepatic portosystemic shunt (TIPS) or other radiological/surgical procedure for portal hypertension treatment
  12. Further exclusion criteria apply
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,590 participants (estimated)

Study arms

  • Experimental
    Survodutide

    Combination Product: Survodutide

  • Placebo comparator
    Placebo

    Combination Product: Placebo matching survodutide

Interventions

  • Combination productSurvodutide

    Subcutaneous injection, pre-filled syringe

    Also known as: BI 456906

  • Combination productPlacebo matching survodutide

    Subcutaneous injection, pre-filled syringe

06

What researchers measure

Primary outcomes

  1. Time to first occurrence of any component of the composite clinical endpoint (at EoS) consisting of: all-cause mortality, liver transplant, hepatic decompensation events, worsening of MELD score to ≥15 and progression to CSPH

    MELD = model of end-stage liver disease CSPH = Clinically significant portal hypertension

    Time frame: up to 4.5 years.

Secondary outcomes

  1. Key secondary endpoint: Absolute change from baseline in enhanced liver fibrosis (ELF) score

    Time frame: At baseline and at Week 76.

  2. Key secondary endpoint: Percentage change from baseline in body weight

    Time frame: At baseline and at Week 76.

  3. Key secondary endpoint: Absolute change from baseline in glycosylated haemoglobin A1c (HbA1c) (%) in participants with type 2 diabetes mellitus (T2DM) at baseline

    Time frame: At baseline and at Week 76.

  4. Key secondary endpoint: Absolute change from baseline in liver stiffness (kPa) in FibroScan® vibration-controlled transient elastography (VCTE)

    Time frame: At baseline and at Week 76.

  5. Percentage change from baseline in liver stiffness in FibroScan® VCTE

    Time frame: At baseline and at Week 76.

  6. Time to first occurrence of progression to CSPH

    Time frame: up to 4.5 years.

  7. Time to first occurrence of any of the hepatic decompensation events (ascites, HE, or portal hypertension-related upper GI bleeding), or worsening of MELD score to ≥15

    Time frame: up to 4.5 years.

  8. Occurrence of all-cause hospitalisation (first and recurrent)

    Time frame: up to 4.5 years.

  9. Time to first occurrence of any of the adjudicated components of the composite endpoint 5-point major adverse cardiac event (5P-MACE)

    Time frame: up to 4.5 years.

  10. Absolute changes from baseline in lipids (mg/dL)

    Time frame: At baseline and at Week 76.

  11. Absolute change from baseline in aspartate aminotransferase (AST) (U/L)

    Time frame: At baseline and at Week 76.

  12. Absolute change from baseline in alanine aminotransferase (ALT) (U/L)

    Time frame: At baseline and at Week 76.

  13. Absolute change from baseline in liver stiffness (kPa) assessed by magnetic resonance elastography (MRE)

    Time frame: At baseline and at Week 76.

07

Study locations

431 of 449 sites recruiting

Showing the first 100 of 449 sites across 37 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Jun 2029, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2024
First posted
Oct 9, 2024
StartActual
Nov 12, 2024
Primary completionEst.
Jun 5, 2029
CompletionEst.
Jun 5, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added, 7 sites removed — first site in Hong Kong. Centro de Investigación y Gastroenterología is now Recruiting
Show 10 added (2 United States, 2 Poland, 1 Czechia, 1 Georgia, 1 Brazil, 1 France, 1 Hong Kong, 1 Switzerland)
  • Vseobecna Fakultni Nemocnice V Praze · Prague, Czechia
  • Israeli - Georgian Medical Research Clinic Healthycore LTD · Tbilisi, Georgia
  • Hospital das Clinicas da Faculdade de Medicina da USP · Cerqueira César, Brazil
  • Dallas Research Institute · Dallas, United States
  • Hopital Beaujon · Clichy, France
  • Prince Of Wales Hospital · Hong Kong, Hong Kong
  • Arizona Liver Health - Chandler Clinic · Chandler, United States
  • FutureMeds Krakow · Krakow, Poland
  • ID Clinic Arkadiusz Pisula · Mysłowice, Poland
  • University Hospital Bern · Bern, Switzerland
Show 7 removed
  • General Faculty Hospital, Prague · Prague, Czechia
  • ISR-GEO Med Res Clin Healthycore · Tbilisi, Georgia
  • Hospital das Clínicas da Faculdade de Medicina da USP · Cerqueira César, Brazil
  • North Texas Research Institute - Dallas · Dallas, United States
  • Hôpital Beaujon · Clichy, France
  • Medical Centre FutureMeds Krakow · Krakow, Poland
  • ID Clinic · Mysłowice, Poland
across 4 updates, Oct 1, 2026 – Nov 12, 2026
Show all 4 updates
  1. Nov 12, 2026
    4 sites added, 2 sites removed
    Show 4 added (2 Poland, 1 United States, 1 Switzerland)
    • Arizona Liver Health - Chandler Clinic · Chandler, United States
    • FutureMeds Krakow · Krakow, Poland
    • ID Clinic Arkadiusz Pisula · Mysłowice, Poland
    • University Hospital Bern · Bern, Switzerland
    Show 2 removed
    • Medical Centre FutureMeds Krakow · Krakow, Poland
    • ID Clinic · Mysłowice, Poland
    + 1 other change: verification date
  2. Oct 28, 2026
    3 sites added, 2 sites removed — first site in Hong Kong. Centro de Investigación y Gastroenterología is now Recruiting
    Show 3 added (1 United States, 1 France, 1 Hong Kong)
    • Dallas Research Institute · Dallas, United States
    • Hopital Beaujon · Clichy, France
    • Prince Of Wales Hospital · Hong Kong, Hong Kong
    Show 2 removed
    • North Texas Research Institute - Dallas · Dallas, United States
    • Hôpital Beaujon · Clichy, France
  3. Oct 14, 2026
    1 site added, 1 site removed
    Show site
    • Hospital das Clinicas da Faculdade de Medicina da USP · Cerqueira César, Brazil
    Show 1 removed
    • Hospital das Clínicas da Faculdade de Medicina da USP · Cerqueira César, Brazil
    + 1 other change: verification date
  4. Oct 1, 2026
    2 sites added, 2 sites removed
    Show 2 added (1 Czechia, 1 Georgia)
    • Vseobecna Fakultni Nemocnice V Praze · Prague, Czechia
    • Israeli - Georgian Medical Research Clinic Healthycore LTD · Tbilisi, Georgia
    Show 2 removed
    • General Faculty Hospital, Prague · Prague, Czechia
    • ISR-GEO Med Res Clin Healthycore · Tbilisi, Georgia

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06632457
Responsible party
Sponsor
First posted
Oct 9, 2024
Start date
Nov 12, 2024
Primary completion
Jun 5, 2029 (estimated)
Completion
Jun 5, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Survodutide

Start the discussion